IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP).
A successful antibiotic stewardship intervention can reduce the usage of fluoroquinolones for patient safety and resistance concerns in community-acquired pneumonia. Read More ›

Investigators evaluated the in vitro activity of omadacycline, a novel aminomethylcycline antibiotic, against a collection of clinical isolates resistant to other available tetracyclines. Read More ›

When considering antibiotic-prescribing guidelines in the community setting, is “one size fits all” applicable in the face of emerging extended-spectrum cephalosporin-resistant Enterobacteriaceae? Read More ›

The efficacy of omadacycline was demonstrated in Gram-positive and Gram-negative clinical isolates from 3 completed phase 3 trials involving tetracycline nonsusceptible pathogens. Read More ›

Researchers compared epidemiologic and healthcare resource utilization data on Escherichia coli community-acquired bacterial pneumonia with that of pneumococcal community-acquired bacterial pneumonia. Read More ›

Omadacycline provides significant improvement in the physical component of quality of life for adult subjects with an acute bacterial skin and skin structure infection known or suspected to be due to a Gram-positive pathogen. Read More ›

Socioeconomic factors play a significant role in hospital readmission following outpatient parenteral antimicrobial therapy. Read More ›

Can costs associated with community-acquired bacterial pneumonia be reduced by implementing the site-of-care indicators regarding severity of illness recommended in the IDSA/ATS CAP guidelines? Read More ›

Eravacycline 1 mg/kg every 12 hours was demonstrated to be noninferior to ertapenem 1 g intravenously every 24 hours or meropenem in patients with complicated intra-abdominal infections. Read More ›

The use of oritavancin is a strategy to address the high economic burden secondary to prolonged hospitalization and high rates of recurrent infections associated with acute bacterial skin and skin structure infections. Read More ›

Page 1 of 3